UP421
Type 1 diabetes
Pre-ClinicalActive
Key Facts
About Sana Biotechnology
Sana Biotechnology is at the forefront of developing a new class of engineered cell therapies designed to be broadly accessible. The company is advancing a pipeline of innovative candidates, including stem cell-derived pancreatic islets for type 1 diabetes and in vivo CAR T therapies for B-cell malignancies and autoimmune disorders. With a seasoned leadership team and a focus on overcoming key challenges in cell therapy like immune rejection and scalable manufacturing, Sana aims to deliver durable, one-time cures for a wide range of serious diseases.
View full company profileTherapeutic Areas
Other Type 1 diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| VX-880 | Vertex Pharmaceuticals | Phase 1/2 |
| VCTX210 (Vertex collab.) | CRISPR Therapeutics | Phase 1/2 |
| SC451 | Sana Biotechnology | Pre-Clinical |
| BioVascular Pancreas™ | Humacyte | Preclinical |
| ORMD-0801 | Oramed Pharmaceuticals | Phase 2 |
| Undisclosed Novel Strategy | CG Scientific | Pre-clinical |